Proficio Capital Partners LLC bought a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 34,637 shares of the company's stock, valued at approximately $1,542,000. Proficio Capital Partners LLC owned approximately 0.07% of Omnicell at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Pier Capital LLC bought a new stake in shares of Omnicell in the 3rd quarter worth $5,859,000. Royce & Associates LP purchased a new position in Omnicell in the 3rd quarter worth about $811,000. Geode Capital Management LLC lifted its stake in Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Omnicell during the 3rd quarter valued at about $753,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Omnicell by 750.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company's stock worth $12,820,000 after acquiring an additional 259,463 shares during the period. Institutional investors own 97.70% of the company's stock.
Insider Transactions at Omnicell
In related news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.64% of the company's stock.
Analyst Ratings Changes
A number of brokerages have weighed in on OMCL. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Thursday. Benchmark reiterated a "buy" rating and set a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America dropped their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. upped their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research report on Thursday, November 21st. Finally, Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $52.33.
Get Our Latest Analysis on OMCL
Omnicell Stock Performance
Shares of OMCL stock traded down $1.05 during trading hours on Monday, reaching $35.94. 445,376 shares of the company traded hands, compared to its average volume of 491,461. The firm has a 50-day moving average price of $41.74 and a 200 day moving average price of $43.64. The company has a market cap of $1.68 billion, a P/E ratio of 133.12, a P/E/G ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.
Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
